Semenov YR, et al. - Given that cutaneous T-cell lymphoma (CTCL) was correlated with a considerable physical, psychological and financial burden, researchers conducted this cross-sectional survey to explore its impact on health-related quality of life (QoL) and economic costs using the Ontario Health Utilities Index Mark 3 (HUI3) questionnaire. Participants in the study were 67 patients with CTCL. Investigators found that CTCL patients had significantly lower aggregate HUI3 scores than the general population. Multivariable regression analysis adjusting for demographics and comorbidities exhibited CTCL was linked to significantly poorer performance overall and in domains of speech, ambulation, emotion, and pain. These decreases in the health utility resulted in an average loss of 1·48 quality-adjusted life-years (QALYs) per patient. CTCL was linked to an individual lifetime burden of $73,889 and US societal burden of $2·86 billion using a $50,000 per QALY willingness-to-pay threshold. These results indicate that CTCL has a widespread impact on QoL, which is comparable to debilitating conditions like an end-stage renal disease. CTCL's substantial economic burden underlines the potential societal advantage of prompt diagnosis and effective management.